Moderna's stock jumped 93% following the announcement that its Phase 3 melanoma trial, conducted with Merck, met its primary endpoint by significantly improving recurrence-free survival when combined with Merck's Keytruda. This marks the first positive Phase 3 result for a personalized mRNA cancer therapy, validating Moderna's platform. The trial involved 1,137 patients and showed no new safety concerns. Both companies are expanding this approach to other cancers, with detailed results and regulatory plans expected at upcoming medical meetings. Investors will watch if Moderna maintains gains above $120 to confirm a lasting valuation shift.
Moderna and Merck reported positive Phase 3 trial results for their personalized mRNA-based cancer vaccine combined with Keytruda, showing significant improvement in recurrence-free survival for melanoma patients. This marks the first successful Phas...
Merck and Moderna announced positive initial results from their first late-stage trial of an experimental personalized cancer vaccine combined with Merck's immunotherapy Keytruda. The phase three trial involving over 1,100 melanoma patients showed th...
